Published • loading... • Updated
‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
Investors are favoring drugmakers with Phase 2 or later data, and 11 of 13 newly public biotech firms raised at least $250 million, BioPharma Dive data shows.
Summary by biopharmadive.com
2 Articles
2 Articles
biopharmadive.comReposted by 
PharmaVOICE
PharmaVOICE‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in offerings later this year — but only among companies fitting a certain criteria.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
